Status:
COMPLETED
Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Peptic Ulcers
Eligibility:
All Genders
50-75 years
Phase:
PHASE4
Brief Summary
The aim of the current study is to replicate the COXA-0508-258 study in a multicenter, US setting, using a lower dose of ASA. It is expected that this study will not only confirm the results of the 25...
Eligibility Criteria
Inclusion
- A healthy adult between 50 and 75 years of age inclusive: of normal clinical laboratory test results during the Screening Visit or, if abnormal, are not clinically significant in the Investigator's opinion.
Exclusion
- A gastric, pyloric channel or duodenal ulcer (defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth) or more than 5 erosions in the stomach or duodenum ( the UGI endoscopic score greater or less) on the baseline UGI endoscopy
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
605 Patients enrolled
Trial Details
Trial ID
NCT00137033
Start Date
September 1 2004
End Date
July 1 2005
Last Update
March 3 2021
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anaheim, California, United States, 92801
2
Pfizer Investigational Site
San Diego, California, United States, 92123
3
Pfizer Investigational Site
Farmington, Connecticut, United States, 06030-0001
4
Pfizer Investigational Site
Waterbury, Connecticut, United States, 06708